Topical Capsaicin for Pain Management: New Lessons From a Very Old Drug-Keith Bley, Ph.D., -05/15/2012 - 8:30am

Event Information
Event Topic: 
Topical Capsaicin for Pain Management: New Lessons From a Very Old Drug
Event Date: 
05/15/2012 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyale, CA
Speaker Information
Event Speaker: 
Keith Bley, Ph.D.,
Event Speaker Title: 
.
Event Speaker Company: 
Solimar Therapeutics
Event Speaker Bio: 

Keith Bley

Keith Bley, Ph.D., is founder and CEO of Solimar Therapeutics. Prior to Solimar, he was Senior Vice President, Nonclinical Research and Development of NeurogesX (NASDQ: NGSX), at which he was a cofounder. During his tenure at NeurogesX, he led the transformation of a concept for pain management into a product (Qutenza®) approved in the US and over 31 other countries. He was also responsible for the conception and early development of the second-generation product (NGX-1998) which has recent shown remarkable success in Phase 2. Prior to NeurogesX, he was a Research Manager in the CNS and pain therapy areas at Roche Palo Alto. Dr. Bley in an inventor on 9 issued patents and is an author on over 30 peer-reviewed publications. His Ph.D. is in Molecular and Cellular Physiology from Yale University.

Event Details
Cost: 
$0
Event Details: 

Capsaicin is the pungent ingredient in chili peppers which is used the world over as a food additive and spice. Capsaicin has been used as a topical analgesic for hundreds of years, but only in 2009 did the FDA formally approve a capsaicin-containing pain medicine. Capsaicin works by first activating and then deactivating sensory nerve fibers in the skin. These same nerve fibers are sometimes pathophysiologically active in chronic pain syndromes. Consequently, inactivating these fibers can produce pain relief without the need for patients to endure the side effects of systemically acting analgesics.

The presentation will provide some ‘hot’ insights into this very old spice and highlight recent advances in our understanding of the processes underlying pain. Implications for future research and opportunities in pain management will be discussed. Also, there will be a case study of what happens when small biopharmaceutical company attempts to introduce a product into a space dominated by big pharma.